Producers can now help prevent bovine respiratory syncytial virus (BRSV)with a single dose of the industry's most researched viral vaccine – Bovi-Shield GOLD.
According to the University of Florida Institute of Food and Agricultural Sciences, BRSV outbreaks will likely result in 100 percent of the cattle in susceptible herds becoming infected, with 20 to 50 percent of animals showing clinical signs and a death loss up to 5 percent.1 With this USDA-approval, Bovi-Shield GOLD now helps provide convenientprotection against BRSV, as well as infectious bovine rhinotracheitis (IBR), parainfluenza-3 (PI3), and bovine virus diarrhea (BVD) types 1 and 2.
"Bovi-Shield GOLD is now approved for both intramuscular and subcutaneous administration, giving producers additional flexibility in their management programs and helping beef producers meet beef quality assurance guidelines,” says Victor Cortese, director of specialty veterinary operations for Pfizer Animal Health. The upgraded formulation of Bovi-Shield GOLD also includes a new virus to help prevent PI3 infections.
Note: These new claims do not apply to Bovi-Shield GOLD® FP® reproductive vaccines.
The Bovi-Shield GOLD line and PregGuard® GOLD FP 10 are recommended for vaccination of healthy cows and heifers approximately 1 month prior to breeding. These products can also be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine prior to breeding initially and within 12 months thereafter. Failure to follow label directions may result in abortions.
The Bovi-Shield GOLD line may be administered to calves nursing pregnant cows, provided their dams were vaccinated within the last 12 months as described above. Consistent with good vaccination practices, heifers should receive at least 2 vaccine doses, with the second dose administered approximately 30 days pre-breeding.
For more information, go to ww.PfizerAH.com.